Articles

Watch Exonate’s Chairman Sunil Shah and Angel Co Fund Investor Peter Cowley, feature in the British Business Bank Finance Guide video

‘Characteristics that make your business investible’ Click here   In January, Exonate was approached by the British Business Bank to feature in a series of videos to highlight their Business Finance Guide. The British Business Bank and Angel Co Fund have provided valuable funding and support to Exonate and our company was highlighted an excellent…

Details

Exonate’s CEO, Dr Catherine Beech to speak at The Commonwealth Innovation Forum (TCIF), Brisbane 2018

Dr Catherine Beech joins a panel highlighting the important contribution that women innovators and entrepreneurs bring to improving healthcare across the globe Cambridge, UK – 3 April 2018: Exonate an early stage biotechnology company, today announces that its CEO Dr Catherine Beech will speak at The Commonwealth Innovation Forum (TCIF) in Brisbane on Thursday 5th…

Details

Watch Exonate’s principal scientist, Dr Jennifer Batson interviewed for Bermuda TV

Watch Exonate’s principal scientist, Dr Jennifer Batson interviewed for Bermuda TV Watch Dr Jennifer Batson as she was interviewed for Bermuda TV during The Bermuda Principles Impact on Splicing 2nd Annual conference on Saturday 24th February 2018. During session 13 ‘Commercialisation of University Research’, Dr Batson presented ‘Developing inhibitors of VEGF-A alternative splicing into a…

Details

Exonate’s principal scientist, Dr Jennifer Batson, to present at The Bermuda Principles Impact on Splicing 2nd Annual conference 2018 (BPIS)

Dr Jennifer Batson will present ‘Developing inhibitors of VEGF-A alternative splicing into a clinical candidate to deliver a paradigm shift in the treatment of retinal vascular diseases’ at Impact on Splicing 2nd Annual Conference 2018 Exonate is developing eye drops to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK – 20 February…

Details

Exonate’s principal scientist, Dr Jennifer Batson, to present at Pharmacology 2017

Dr Jennifer Batson will present ‘A Paradigm Shift in the Treatment of Retinal Vascular Diseases’ at Pharmacology 2017 on Tuesday 12 December 2017 Exonate is developing eye drops to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK – 11 December 2017: Exonate an early stage biotechnology company, today announces that its principal…

Details

Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)

Ophthalmology leaders to support early stage biotechnology company with potential to revolutionise current standard-of-care in the treatment of eye diseases   Cambridge, UK – 8 November: Exonate, an early stage biotechnology company, today announces the formation of its Clinical Advisory Board (CAB) to support the scientific, pre-clinical development of a revolutionary eye-drop treatment for retinal…

Details

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need   Cambridge, UK. Monday 6th February 2017 – Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development of an eye – drop treatment for wet age–related macular degeneration.  …

Details

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD) New and existing investors participated in the round Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Wednesday [30th] November 2016 – Exonate, an early stage biotechnology company, today announced they…

Details